Full-Time
CRISPR-Cas9 genome-editing therapeutics developer
$213.1k - $260.4k/yr
Cambridge, MA, USA
Hybrid
Hybrid role with expected on-site attendance; employees are expected to meet the required time on site.
Master's, PhD
See people who can refer or advise you
Intellia Therapeutics develops CRISPR-Cas9 genome editing therapies to treat severe genetic diseases. Its work centers on using CRISPR to edit genes and delivering the editing tools to the right cells with a modular lipid nanoparticle system, aiming to create treatments that can be given to patients and move through clinical trials toward market. The company earns revenue through R&D collaborations, licensing, and potential sales of approved therapies. Compared to others in biotech, Intellia emphasizes in vivo gene editing using a distinctive lipid nanoparticle delivery approach and active partnerships to advance candidates. Its goal is to bring safe, effective genome-editing treatments to patients while building value through collaborations and licensing.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2014
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
Stock Options
Company Equity
401(k) Retirement Plan
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Professional Development Budget
Conference Attendance Budget
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Family Planning Benefits
Fertility Treatment Support
Parenting Leave
Adoption Assistance
Childcare Support
Elder Care Support
Commuter Benefits
Meal Benefits
Employee Discounts
Company Social Events
Intellia Therapeutics, Inc. secures non-dilutive debt facility with OrbiMed for up to $400 million. Published on 09/04/2026 at 12:06 pm EDT S&P Capital IQ Intellia Therapeutics, Inc. announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm. The facility includes an initial term loan of $75 million that was funded at closing; 5 additional tranches totaling up to $225 million that can be drawn at Intellia?s option subject to its achievement of specified milestones related primarily to lonvo-z; and an additional $100 million available subject to mutual agreement between the parties during the five-year term of the agreement. Additional details of the loan agreement will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K. TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia. Covington & Burling LLP acted as legal advisor to OrbiMed. (C) S&P Capital IQ - 2026
Intellia Therapeutics has secured a $400 million non-dilutive senior secured term loan facility with OrbiMed. The deal includes an initial $75 million funded at closing, with up to $225 million available in additional tranches subject to achieving milestones related to lonvoguran ziclumeran (lonvo-z), its treatment for hereditary angioedema. Another $100 million may be available by mutual agreement during the five-year term. The financing provides Intellia with financial flexibility as it prepares for a planned US approval and commercial launch of lonvo-z. "This non-dilutive financing enables us to more freely execute our plan to successfully launch lonvo-z in HAE, advance nexiguran ziclumeran through multiple important milestones in transthyretin amyloidosis and create value through our early pipeline development efforts," said Edward Dulac, Intellia's chief financial officer. TD Cowen acted as exclusive financial adviser to Intellia on the transaction.
6 companies hiring in Cambridge now. July 22, 2026 | Looking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year. Life sciences professionals looking for employment in Cambridge, Massachusetts, may find more opportunities in that part of the Genetown Hotbed now than they did a year ago. Job postings live on the BioSpace website for Cambridge jumped 120% year over year. They started trending up in February, with only a slight dip in May before rising again last month. If you're interested in working at a pharma or biotech in Cambridge, check out the open positions at these six companies. * Intellia Therapeutics has around 40 jobs available. Roles include vice president, gene editing core; senior director, quality management systems and compliance; and manager, commercial systems. * Regeneron has about a dozen openings. Jobs include scientist-analytical development, Regeneron cell medicines; senior toxicologist; and senior manager clinical study lead (clinical experimental sciences). * Sanofi has over 100 roles available. Positions include senior associate scientist; clinical research director; and director, commercial transformation. * AbbVie has several openings. Jobs include associate scientist, cellular/molecular biochemistry II; senior scientist II, rheumatology; and senior principal scientist, immune cell depletion discovery group, immunology discovery research. * Amgen also has several positions available. Roles include senior quality engineer; process development senior scientist-pivotal drug product technologies; and device engineering senior engineer. * Moderna has over 50 openings. Jobs include scientist, oncology bioinformatics; manager, biomarker operations; and senior research associate, in vivo pharm. Job market trends, layoffs and career advice to manage your life sciences career Angela Gabriel is content manager, life sciences careers, at BioSpace. She covers the biopharma job market, job trends and career advice, and produces client content. You can reach her at [email protected] and follow her on LinkedIn.
Intellia Therapeutics, a clinical-stage biotech focused on CRISPR-based gene editing, reported FY 2025 revenue of $67.7 million, up 17% year-over-year, though it posted a net loss of $412.7 million. The company maintains a conservative debt-to-equity ratio of 0.1x and collaborates with Regeneron Pharmaceuticals on neurological and muscular disease treatments. Omeros, transitioning to commercial stage following FDA approval of Yartemlea for transplant-associated thrombotic microangiopathy in late 2025, reported no FY 2025 revenue but improved its net loss to $3.4 million. The company holds $135.3 million in cash against $226.6 million in debt and has partnered with Novo Nordisk on zaltenibart development. Both companies operate in high-risk biotech sectors with distinct strategies.
Intellia Therapeutics presents additional results from Phase 3 HAELO trial. Jun. 14, 2026, 02:35 PM Intellia Therapeutics (NTLA) presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema, HAE, in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology, EAACI, Annual Congress 2026 in Istanbul, Turkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. Today's presentation and publication also included supplemental demographics, data and analyses, including: A time plot showing that the mean monthly attack rate for patients receiving lonvo-z through the data cutoff was well below the reported rate in prescreening while patients were receiving standard-of-care therapy; Patient-level data demonstrating that all patients in the lonvo-z arm experienced attack-rate reductions from baseline during weeks 5 to 28; An analysis showing that meaningful attack-rate reductions were observed for all evaluated subgroups; A breakdown showing that 20% of the patients who enrolled in HAELO reported having complete disease control as their best response to prior long-term prophylaxis therapies; and A plasma kallikrein time plot showing that protein levels decreased substantially by the first measurement, reached a steady state by week 5 and remained stable through the data cutoff. * Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. * Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Published first on TheFly - the ultimate source for real-time, market-moving breaking financial news. Try Now>> Read More on NTLA: